• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Connect with Us
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

American College of Chest Physicians (CHEST) 2021 Annual Meeting

October 17-20, 2021

  1. Tezepelumab
  2. Benralizumab
  3. Budesonide/Glycopyrronium/Formoterol (PT010)
  4. PRECISION
  5. CHRONICLE
  6. Real-World Evidence - Asthma
  7. Real-World Evidence - COPD

Html

Efficacy of tezepelumab in patients with severe, uncontrolled asthma grouped by baseline body mass index in the NAVIGATOR study

Html

Effect of tezepelumab on lung function in patients with severe, uncontrolled asthma in the phase 3 NAVIGATOR study

Html

Rapid improvement in morning and evening peak expiratory flow in patients with severe, uncontrolled asthma treated with tezepelumab

Html

Tezepelumab produces clinically meaningful responses on patient-reported outcome measures in patients with severe, uncontrolled asthma: Results from the phase 3 NAVIGATOR study

Html

Eosinophils and interleukin-5 receptor in COVID-19 post-mortem lung tissue

Html

5-year US COPD exacerbation costs extrapolated from the ETHOS study

Html

Triple therapy reduces COPD exacerbations requiring systemic corticosteroids: A post-hoc analysis of the ETHOS study

Html

Reproducibility of the Asthma Impairment and Risk Questionnaire (AIRQ)

Html

Biologic medications for severe asthma are effective in the real-world, including in subgroups not studied in randomized trials

Html

Relations of annual short-acting beta2-agonist and systemic corticosteroid exposures with adverse health conditions in adults and adolescents with asthma

Html

Overlap of asthma with ABPA and EGPA by disease severity, eosinophil levels, health care resource utilization, and costs

Html

Variations highlighted in hyperlocal heatmaps can address unmet need and allocation of resources in COPD

Html

Prompt initiation of maintenance therapy in the United States (PRIMUS): An analysis of triple therapy following a disease exacerbation among patients with COPD

Need Help?

Contact Us

Find an MSL

Chat with a Medical Affairs Associate

Send MIR

Submit a Medical Information Request

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. Med Co has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am a payer or formulary decision-maker
I am neither (take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2022 AstraZeneca. All rights reserved.

US-69609

Last Updated 11/22

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Privacy Notice

Legal Notice

Cookie Notice

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Pharma Logo

Privacy NoticeLegal NoticeCookie Notice